Market closed · Next open: Monday 9:30 AM ET
Last update: Oct 30, 2026, 6:17 PM ET

Stock Analysis

SiTime Stock (SITM) Falls 14.6% in a Chip Rout: What Actually Changed

SiTime stock fell 14.6% on July 2, dragged down by a semiconductor selloff one day after completing its Renesas timing acquisition. The move says more about positioning and valuation than about the business.

By Roberto LiccardoPublished (ET)6 min readSITM
SiTime-branded timing chip on a dark circuit board beside a glowing clock face, illustrating precision timing in semiconductors.

Why did SiTime stock drop 14.6%?

SiTime stock (SITM) dropped 14.6% on July 2, 2026, closing at $601.66, because a macro-driven selloff hit semiconductor stocks and punished high-multiple names hardest — not because of negative company news [1][2].

There was no earnings report or downgrade on July 2, but the session wasn't news-free either: SiTime had completed its acquisition of Renesas' timing business one day earlier, on July 1, and filed an 8-K disclosing the final consideration and related financing [6][7]. Still, the main force was the sector: the VanEck Semiconductor ETF (SMH) lost 4.4%, the worst industry group of the day, while the Nasdaq 100 dropped 1.9% and the Dow set a record high [2].

The trigger was macro. June nonfarm payrolls came in at 57,000, roughly half the 113,000 consensus, with inflation still running at 4.2%. An awkward mix for a market bracing for a possible Fed hike, and high-multiple chip names took the brunt [2].

Even after the drop, SITM is up 70.3% year to date and 187.4% over twelve months [1].

What changed for SITM on July 2?

The July 2 session was a sector event that hit SiTime harder than the sector. SMH fell 4.4%, the tech sector fund XLK lost 2.6%, the Nasdaq 100 dropped 1.9%, and the S&P 500 slipped just 0.3% [2]. SITM fell 14.6% [1]. Micron, KLA and Lam Research were all sharply lower too, but the steepest losses in the group belonged to smaller, higher-multiple names [2].

Bar chart comparing July 2, 2026 declines: SiTime down 14.6%, Vicor down 12.6% intraday, SMH down 4.4%, XLK down 2.6%, Nasdaq 100 down 1.9%, S&P 500 down 0.3%.
SITM fell roughly three times as hard as the chip sector ETF on July 2. Session of Jul 2, 2026; reported market data.

This also wasn't the first down day. The stock is off 11.0% over the past week and 14.2% over the past month [1], so momentum had been cooling for a while before Thursday's rout made it obvious.

The pullback follows a very strong run. Q1 2026 results on May 6 showed revenue of $113.6 million and non-GAAP EPS of $1.44 [3], and a Barclays upgrade the next day helped send the shares up about 28% on May 7, to a close of $797.31 [8]. The 52-week range tells you how wide the swings have been: a low of $186.49 and a high of $901.81 [1].

Bar chart of SiTime returns as of July 2, 2026: down 14.6% in one day, down 11.0% in one week, down 14.2% in one month, up 70.3% year to date, up 187.4% over one year.
One bad day against a large 12-month gain. Returns as of Jul 2, 2026 close; reported market data.

Why the drop matters for SiTime stock

For holders, the useful question is whether Wednesday revealed anything new about SiTime. On the operating side, it didn't. The Q1 numbers were strong, and the Elite 2 Super-TCXO, a timing product aimed at synchronization inside AI data centers, is sampling now with commercial production planned for Q3 2026 [3]. The AI data-center demand story that drove the rally is intact.

What the drop does expose is how much sensitivity has built up around the stock. Three things amplify moves like this one. First, valuation: even after the decline, a P/S ratio near 47.6x leaves little room for disappointment [4]. Second, the balance sheet is busier than it used to be. SiTime completed the Renesas timing acquisition on July 1, paying roughly $1.5 billion in cash plus 3,558,691 newly issued shares [7], and it carries $1.35 billion of zero-coupon convertible notes issued to help fund the deal [4]. Dilution and integration are now live items, not pending ones. Third, the market has punished SiTime for capital raises before: shares fell after the company announced a $350 million public offering, on dilution concerns [5].

None of these items is new. A day like July 2 just reprices how much investors are willing to pay to hold them.

What to watch next for SITM

Near term, the sector matters more than the company. Watch whether SMH stabilizes or keeps sliding; SiTime has amplified sector moves in both directions all year, including a 28% single-day gain in May [8] and a double-digit drop in March.

On the macro side, the Fed path is the live variable. After the payrolls miss, odds of a September rate hike fell to roughly 50% from about 64% a day earlier, and Fed Chair Kevin Warsh has signaled little urgency to tighten further [2]. Softer rate expectations would help high-multiple names like this one; hotter inflation prints would do the opposite.

Company-specific markers to track now center on Renesas integration: the acquired business's revenue contribution against management's target of at least $300 million in its first twelve months [6], its effect on gross margins, and how the dilution from the deal shares and the convertible-note debt load flow through per-share numbers. Beyond the deal, watch the Q3 2026 production ramp of the Elite 2 product line, the next earnings report and whether management's AI and data-center demand commentary holds its tone, and the pace of insider selling. If the fundamentals keep delivering while the multiple compresses, the risk profile of the stock changes even if the business doesn't.

Did SiTime stock fall because of the Renesas deal?

Mostly no: the July 2 drop tracked a sector-wide semiconductor selloff, and the Renesas closing had been announced in February and expected for months [2][7]. The deal matters mainly as an amplifier — the 3,558,691 newly issued shares and the convertible debt make SITM more sensitive on risk-off days [4][7].

Why did SITM fall harder than other chip stocks?

  • Valuation left no cushion. Roughly 47.6x sales versus a semiconductor industry average of 8.8x [4].
  • Crowded momentum ownership. The stock was up 187.4% over twelve months going into the session, so it carried a large base of gains to protect [1].
  • Dilution became concrete. The Renesas closing on July 1 issued 3,558,691 new shares and finalized deal financing [7].
  • Insider selling removed a support signal. $367 million sold over the prior three months, with no reported buying [1].
  • High-beta names led the losses. Vicor fell about 12.6% intraday in the same session; smaller high-multiple chip names dropped far more than the group [2].

SITM vs chip peers and benchmarks on July 2, 2026

The comparison shows how concentrated the damage was: the further out the risk curve, the harder the fall.

NameJuly 2 moveBaselineWhat it is
SiTime (SITM)−14.6%Prior close → $601.66 close [1]MEMS precision-timing chips
Vicor (VICR)~−12.6%Intraday, as reported [2]Power modules
SMH−4.4%Full session [2]Semiconductor sector ETF
XLK−2.6%Full session [2]Technology sector ETF
Nasdaq 100−1.9%Full session [2]Large-cap tech index
S&P 500−0.3%Full session [2]Broad market index

Figures per cited reporting; approximate where marked (~). Baselines are stated per row; the SITM figure is close-to-close, the VICR figure was reported intraday.

What could move SITM next?

  • Q2 2026 earnings (expected early August, not yet scheduled). The first report to include any Renesas contribution; Q1 was reported May 6 [3].
  • Elite 2 Super-TCXO volume production (Q3 2026). The AI data-center timing product moves from sampling to commercial production [3].
  • The Fed's September decision. Hike odds sat near 50% after the payrolls miss; a shift either way repriced high-multiple chip names all year [2].
  • Renesas integration milestones. Progress against management's target of at least $300 million of revenue from the acquired business in its first twelve months [6].
  • Insider filings. Whether the recent pace of selling continues or slows [1].

SiTime stock FAQ

What does SiTime do?

SiTime (NASDAQ: SITM) is a Santa Clara-based semiconductor company that designs MEMS-based precision timing products — oscillators, clocks and resonators that synchronize signals in AI data centers, communications networks, industrial systems and other electronics.

Did SiTime report bad news on July 2, 2026?

No. There was no earnings report or downgrade. The 14.6% drop tracked a sector-wide semiconductor selloff triggered by a weak June payrolls print. One day earlier, on July 1, SiTime completed its previously announced acquisition of Renesas' timing business.

What did SiTime pay for Renesas' timing business?

At the July 1, 2026 closing, SiTime paid approximately $1.5 billion in cash plus 3,558,691 newly issued shares of its common stock, per the company's 8-K filing.

Is SiTime stock still up in 2026?

Yes. Even after the July 2 decline to $601.66, SITM was up 70.3% year to date and 187.4% over the trailing twelve months, per reported market data as of that close.

When are SiTime's next earnings?

SiTime reported Q1 2026 results on May 6, 2026. Q2 2026 results are expected around early August 2026 based on the company's usual cadence, but the date had not been officially announced as of this writing.

View all research →
An abstract visualization of a falling stock chart over a search and AI motif in orange-red tones, representing Reddit's crash after a Q3 revenue beat was overshadowed by a Google AI search-traffic warning.
Stock AnalysisOctober 30, 2026 · 12 min read

Reddit (RDDT) Crashes ~30% After a Q3 Beat on a Google AI Search-Traffic Warning

Reddit crashed about 30% to roughly $90.79 on October 30 — a striking reaction, because the quarter itself was strong: revenue of $895 million rose 53% year over year, a clear beat, with net income of $283 million, diluted EPS of $1.40 and adjusted EBITDA of $402 million. The stock cratered on what management said about the future. On the earnings call, CEO Steve Huffman warned that search referrals fell more than a million per week on average in October as Google answers more queries with AI, and that daily active users (around 130 million) could fall a low-double-digit percentage in the fourth quarter if the trend held. Investors also fixed on a 2% year-over-year decline in US daily actives — Reddit's most valuable market, where revenue per user is more than five times the international level — and on fourth-quarter revenue guidance of $1.00–$1.03 billion that came in below expectations; Citizens downgraded the stock before the open. The one bullish counterweight was monetization: revenue per user still jumped 36% globally. The move was company-specific — Reddit's roughly 30% drop was about four times the moves of social peers Snap and Pinterest (each down ~7%), on a day the broad market fell about 2%. After the crash Reddit trades at roughly 14 times forward earnings with about $3 billion of net cash — not expensive for 50%-plus growth, if the growth is durable. The whole debate is whether rising revenue per user can keep outrunning a top of the funnel that AI search is draining.

An abstract visualization of a falling stock chart over an automotive and circuit-grille motif in steel-blue and red tones, representing General Motors' drop after a Q3 beat-and-raise was overshadowed by 2027 cost and EV concerns.
Stock AnalysisOctober 20, 2026 · 10 min read

General Motors (GM) Falls ~8% Despite a Q3 Beat and a $20B Buyback

General Motors fell about 8% to roughly $75.77 on October 20 — a striking reaction, because GM beat on third-quarter earnings, raised its full-year profit outlook and announced a $20 billion buyback. Adjusted earnings of $3.70 a share topped estimates on revenue of about $50 billion, and GM lifted the midpoint of its full-year adjusted-EPS guidance to about $13.25 (from $13.00) and raised its free-cash-flow outlook. The stock fell anyway on what the guidance implied, not the quarter. The full-year outlook implies a softer fourth quarter — only about $2.7 billion of operating profit versus $4.1 billion in the third, as a Silverado/Sierra redesign temporarily cuts truck deliveries by roughly 35,000 units — the raised $13.25 EPS midpoint still landed just below the roughly $13.41 the Street expected, and management flagged about $2 billion of 2026 cost inflation plus a conditional scenario of more in 2027. Two things that look like culprits mostly were not: the 62% drop in EV sales was already known and reflects a distorted 2025 comparison, and tariff costs are now expected near the low end of an existing range. Crucially, GM did not cut its 2027 outlook — it still expects next year to improve if conditions hold. The move was clearly company-specific — Ford fell only about 1%, Stellantis was flat and the S&P 500 rose — so this was a repricing of GM's forward earnings, not an auto-sector sell-off. The valuation captures the tension: GM trades at barely five to six times the forward earnings it guides to, extraordinarily cheap, because the market prices automakers for the downturn, not the peak. A $20 billion buyback into that multiple is powerfully accretive if earnings hold — but whether they hold in 2027 is exactly the question. Analysts keep a Buy consensus and an average target near $104.

An abstract visualization of a rising stock chart over a molecular antibody and DNA-helix motif in cool teal and violet tones, representing Summit Therapeutics' jump on a new ivonescimab kidney-cancer trial.
Stock AnalysisOctober 19, 2026 · 10 min read

Summit Therapeutics (SMMT) Jumps ~6% on a New Ivonescimab Kidney-Cancer Trial

Summit Therapeutics rose about 6% to roughly $15.57 on October 19 after announcing it had opened a global Phase II trial of ivonescimab — its closely watched lead drug — in previously untreated advanced clear cell kidney cancer, with partner Akeso. The key nuance: this is the opening of a mid-stage study, not a data readout, so it is an incremental catalyst that expands the story rather than one that proves it. Summit is effectively a one-drug company: ivonescimab is a PD-1/VEGF bispecific antibody, licensed from China's Akeso, that outperformed Merck's Keytruda in a Chinese lung-cancer trial — nearly doubling progression-free survival and, in updated data, delivering a significant overall-survival benefit (30.8 vs 22.6 months) — though the global trial behind its U.S. filing has yet to formally confirm that survival benefit in Western patients. With no product revenue and a market value above $12 billion, essentially all of Summit's worth is the market's bet on that drug, so a new indication is a fresh call option on the thesis. Two bigger items frame it: AstraZeneca agreed in late September to invest about $2 billion in Summit equity (a ~12% stake), transforming the balance sheet and removing the financing overhang, and the FDA has a November 14, 2026 decision date on ivonescimab in EGFR-mutated lung cancer — a near-term, binary catalyst that matters far more than a trial start. Monday's move was partly company-specific and partly a tailwind: biotech broadly rallied, with the sector ETF up about 2.5%, but Summit outperformed. The risks are a binary valuation on one molecule, an unconfirmed Western survival benefit, and a stock down roughly 47% from its high. Analysts carry a Buy consensus and an average target near $30, inside a wide range from about $12 to the mid-$40s.